Daily Endocrinology Research Analysis
Analyzed 84 papers and selected 3 impactful papers.
Summary
Three standout endocrinology papers span therapeutic efficacy, real-world outcomes, and mechanistic insight. A phase 3a RCT in East Asia shows fixed-dose cagrilintide–semaglutide yields markedly greater weight loss than semaglutide alone. A large emulated target trial links GLP-1 receptor agonists to lower incident CKD, dialysis, AKI, MACE, and mortality versus DPP-4 inhibitors, while a multi-omic human kidney study maps a HIF-centered hypoxia network that is reversed with SGLT2 inhibition.
Research Themes
- Combination incretin and amylin-pathway therapy for obesity in East Asian populations
- Renal and cardiovascular protection with GLP-1 receptor agonists in type 2 diabetes
- Hypoxia/HIF regulatory networks in diabetic kidney disease and modulation by SGLT2 inhibitors
Selected Articles
1. Efficacy and safety of co-administered cagrilintide and semaglutide versus semaglutide alone in adults with overweight or obesity with or without type 2 diabetes in Japan and Taiwan (REDEFINE 5): a multicentre, randomised, active-controlled, phase 3a trial.
In a multicenter, double-blind phase 3a RCT in Japan and Taiwan (n=331), fixed-dose cagrilintide 2.4 mg plus semaglutide 2.4 mg produced 6.5 percentage points greater mean weight loss at 68 weeks than semaglutide 2.4 mg alone. Adverse events were mainly gastrointestinal and similar between groups; discontinuations were low and one non–treatment-related death occurred in the semaglutide arm.
Impact: Provides high-quality, region-specific RCT evidence that a fixed-dose amylin-pathway and incretin combination substantially augments weight loss over a current standard therapy in East Asian populations.
Clinical Implications: For adults with overweight/obesity (with or without type 2 diabetes), combining cagrilintide with semaglutide can deliver clinically meaningful additional weight loss with comparable tolerability, potentially informing escalation strategies in obesity pharmacotherapy in Asian populations.
Key Findings
- Mean bodyweight change at week 68: −18.4% with cagrilintide–semaglutide vs −11.9% with semaglutide (ETD −6.5 percentage points; 95% CI −8.4 to −4.6; p<0.0001).
- Adverse events occurred in 87% vs 84% (combination vs semaglutide), mostly gastrointestinal, with similar profiles across groups.
- Discontinuation rates were low (10% vs 6%); one death in the semaglutide arm was deemed not treatment-related.
Methodological Strengths
- Multicenter, randomized, double-blind, active-controlled phase 3a design with prespecified endpoints.
- Consistent safety monitoring and parallel-group allocation with adequate sample size for regional inference.
Limitations
- Conducted in Japan/Taiwan; generalizability to broader, more diverse populations and longer-term outcomes remains to be determined.
- Industry-funded trial; duration limited to 68 weeks without long-term cardiometabolic outcome data.
Future Directions: Evaluate durability, cardiometabolic outcomes, and real-world effectiveness across diverse Asian and non-Asian populations; compare head-to-head with other advanced anti-obesity agents (e.g., tirzepatide); refine dosing/titration strategies.
BACKGROUND: The combination of cagrilintide and semaglutide has been shown in global studies to induce reductions in bodyweight. We assessed the efficacy and safety of a fixed-dose combination of cagrilintide 2·4 mg and semaglutide 2·4 mg versus semaglutide 2·4 mg for weight management in an east Asian population. METHODS: This double-blind, parallel-group, phase 3a trial (REDEFINE 5) was conducted across 21 sites (community, hospital) in Japan and one site in Taiwan. We included participants aged at least 18 years with a BMI of at least 27 kg/m FINDINGS: Between April 3, 2023, and Sept 15, 2023, we screened 355 individuals; 331 were randomly assigned to cagrilintide-semaglutide (n=164) or semaglutide (n=167). 226 (68%) participants were male and 105 (32%) were female; 80 (24%) had type 2 diabetes. 17 (10%) participants discontinued cagrilintide-semaglutide and ten (6%) discontinued semaglutide. The estimated mean change in bodyweight from baseline to week 68 was -18·4% (SE 0·7) in the cagrilintide-semaglutide group versus -11·9% (0·7) in the semaglutide group (estimated treatment difference [ETD] -6·5 percentage points [95% CI -8·4 to -4·6]; p<0·0001). Adverse events were reported by 143 (87%) of 164 participants in the cagrilintide-semaglutide group and 141 (84%) of 167 in the semaglutide group, the most common of which were gastrointestinal disorders (87 [53%] of 164 participants in the cagrilintide-semaglutide group vs 85 [51%] of 167 in the semaglutide group). One death was reported in the semaglutide 2·4 mg group, which was not judged to be treatment related by the investigator. INTERPRETATION: These findings support the efficacy and safety of cagrilintide-semaglutide for weight management in individuals from east Asia with overweight or obesity, with or without type 2 diabetes. FUNDING: Novo Nordisk. TRANSLATIONS: For the Japanese and Mandarin translations of the abstract see Supplementary Materials section.
2. Hypoxia inducible factor network reflects kidney disease progression in diabetes and sodium-glucose co-transporters inhibition.
A promoter-anchored, 237-gene HIF regulatory network was delineated across kidney cell types in diabetes, increased with DKD progression, and validated in hypoxic human organoids. Notably, tissues from SGLT2i-treated individuals with T2D showed reversal of HIF-network changes, supporting a hypoxia-modulating mechanism of SGLT2i and offering a multi-component biomarker framework.
Impact: Provides a mechanistic, multi-omics bridge between hypoxia signaling and SGLT2i renoprotection with convergent validation in human tissue, organoids, and spatial transcriptomics.
Clinical Implications: Suggests a quantifiable HIF-network signature as a translational biomarker for DKD progression and SGLT2i response, potentially guiding patient stratification and therapeutic monitoring beyond glycemic indices.
Key Findings
- A 237-gene, 7-pathway HIF regulatory network was identified using promoter motif analyses and single-cell data, with 80% of genes in accessible chromatin.
- Network expression increased from early to late DKD and was validated in hypoxic human kidney organoids.
- In T2D kidney tissue, SGLT2 inhibitor treatment was associated with reversal of HIF-network alterations; findings were concordant in spatial transcriptomics.
Methodological Strengths
- Integration of single-cell transcriptomics, promoter motif analysis, multiome chromatin accessibility, organoid validation, and spatial transcriptomics.
- Replication across early and late DKD cohorts (KPMP) and treatment-exposed human tissues.
Limitations
- Exact sample sizes per modality were not detailed; observational tissue analyses limit causal inference.
- Clinical endpoints were not assessed; generalizability beyond studied cohorts requires prospective validation.
Future Directions: Prospectively validate the HIF-network as a predictive/prognostic biomarker for DKD and as a pharmacodynamic readout for SGLT2i; test network modulation across antidiabetic drug classes and in interventional trials.
Hypoxia drives diabetic kidney disease (DKD) progression through Hypoxia Inducible Factor (HIF) signaling. The kidney's cellular heterogeneity and complex architecture pose challenges for directly assessing the pharmacologic effects on kidney oxygenation and hypoxia-responsive pathways in vivo, such as treatment with SGLT2 inhibitors (SGLT2i), presumed to impact kidney oxygenation. Using single-cell transcriptional profiling of kidney tissue from youth with type 2 diabetes (T2D) who showed minimal clinical evidence of DKD, we identified cell type enrichment of HIF-regulated genes, findings that replicated in people with later-stage DKD in the Kidney Precision Medicine Project (KPMP). Using conserved transcription factor (TF) binding motifs, higher-order promoter regulatory structures identified potential cooperating TFs that explained the cell type enrichment pattern. From these promoter elements, 7 interconnected regulatory pathways were identified, comprising a network of 237 genes. Analysis of multiome data from reference tissue in KPMP demonstrated that 80% of the network genes resided in accessible chromatin. Expression of network genes increased significantly in the late compared to the early stage DKD and was validated in a hypoxic human organoid model system. Kidney tissue from individuals with T2D treated with SGLT2i demonstrated reversal of the accumulated changes in the HIF network compared to those not treated with SGLT2i. Most high-confidence genes showed concordant differential expression in spatial transcriptomics from individuals with T2D. Hypoxic kidney organoids treated with SGLT2i confirmed these protective effects. Our promoter-anchored HIF regulatory network provides a multi-component read-out that captures disease progression and quantifies therapeutic response to SGLT2i.
3. Association of GLP-1 Receptor Agonist Use With Chronic Kidney Disease Risk in Type 2 Diabetes: Multicenter Emulated Target Trials.
Across 24,510 matched pairs of new GLP-1 RA versus DPP-4i users without baseline CKD, GLP-1 RAs were associated with lower risks of incident CKD, dialysis, AKI, MACE, and all-cause mortality. Benefits were consistent in subgroup analyses and supported by Kaplan–Meier curves showing reduced cumulative incidence.
Impact: Real-world, multicenter emulated target trials demonstrate broad renal and cardiovascular benefits of GLP-1 RAs versus DPP-4is in T2D without baseline CKD, informing agent selection beyond glycemic control.
Clinical Implications: Supports preferential consideration of GLP-1 RAs (when not contraindicated) in T2D patients at risk for CKD and cardiovascular events, while acknowledging residual confounding inherent to observational designs.
Key Findings
- GLP-1 RA initiation vs DPP-4i reduced composite kidney outcomes (HR 0.85; 95% CI 0.82–0.87) and incident CKD (HR 0.85; 95% CI 0.82–0.88).
- Marked reductions in dialysis (HR 0.53; 95% CI 0.43–0.64) and AKI (HR 0.81; 95% CI 0.76–0.86).
- Lower MACE (HR 0.84; 95% CI 0.81–0.88) and all-cause mortality (HR 0.55; 95% CI 0.50–0.59); benefits consistent across subgroups.
Methodological Strengths
- Target trial emulation with large, multicenter EHR network and propensity score matching in 24,510 pairs.
- Consistent findings across multiple hard outcomes and subgroup analyses with Kaplan–Meier confirmation.
Limitations
- Observational design subject to residual confounding, misclassification, and unmeasured variables (e.g., adherence).
- Exposure/comparator limited to GLP-1 RA vs DPP-4i; head-to-head vs SGLT2i or other agents not assessed.
Future Directions: Conduct pragmatic RCTs or advanced causal inference analyses (e.g., instrumental variables, target trial replications) to confirm renal protection; compare directly with SGLT2 inhibitors and evaluate combination strategies.
OBJECTIVE: To determine whether glucagon-like peptide-1 receptor agonist (GLP-1 RA) initiation is associated with reduction of incident renal outcomes compared with dipeptidyl peptidase-4 inhibitors (DPP-4is) in patients with type 2 diabetes (T2D) without pre-existing chronic kidney disease (CKD). METHODS: This study identified 370,636 patients with T2D from the TriNetX Collaborative Network database between January 1, 2015, and June 30, 2023. An emulated target trial was constructed, comprising 24,510 propensity score-matched pairs of new users of GLP-1 RAs and DPP-4is. Composite CKD events (defined as a combination of CKD diagnosis, estimated glomerular filtration rate <60 mL/min per 1.73 m RESULTS: Participants were 57.6±12.0 years of age and 48.9% were male. Compared with DPP-4i users, GLP-1 RA users had significantly reduced risks of composite kidney outcomes (HR, 0.85; 95% CI, 0.82 to 0.87), incident CKD (HR, 0.85; 95% CI, 0.82 to 0.88), dialysis (HR, 0.53; 95% CI, 0.43 to 0.64), acute kidney injury (HR, 0.81; 95% CI, 0.76 to 0.86), major adverse cardiac events (HR, 0.84; 95% CI, 0.81 to 0.88), and all-cause mortality (HR, 0.55; 95% CI, 0.50 to 0.59). Kaplan-Meier analyses confirmed lower cumulative incidence of these outcomes in GLP-1 RA users. Subgroup analyses confirmed consistent benefits across various patient groups. CONCLUSION: In patients with T2D and no prior CKD, GLP-1 RA use was associated with lower risks of renal complications, incident CKD, cardiovascular events, and death compared with DPP-4is.